Immunological Treatment Options for Locoregionally Advanced Head and Neck Squamous Cell Carcinoma

No abstract is available for this paper.

• Publication year

  2012

• Venue

  International Reviews of Immunology

• Publication date

  2012-01-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.3109/08830185.2011.637253PMID 22251006PMCID PMC4164222
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cannabinoid-1 receptor (CB1R) blockers as medicines: beyond obesity and cardiometabolic disorders to substance abuse/drug addiction with CB1R neutral antagonists

  2012cited by this paper
• Cetuximab induces mitochondrial translocalization of EGFRvIII, but not EGFR: involvement of mitochondria in tumor drug resistance?

  2012cited by this paper
• Clinical Results of Definitive Chemoradiotherapy for Patients With Synchronous Head and Neck Squamous Cell Carcinoma and Esophageal Cancer

  2011cited by this paper
• Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.

  2011cited by this paper
• Generating HPV specific T helper cells for the treatment of HPV induced malignancies using TCR gene transfer

  2011cited by this paper
• Expression of Amphiregulin and EGFRvIII Affect Outcome of Patients with Squamous Cell Carcinoma of the Head and Neck Receiving Cetuximab–Docetaxel Treatment

  2011cited by this paper
• Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer.

  2011cited by this paper
• Human papillomavirus and survival of patients with oropharyngeal cancer.

  2010cited by this paper
• Approval of provenge seen as first step for cancer treatment vaccines.

  2010cited by this paper
• Emerging drugs to treat squamous cell carcinomas of the head and neck

  2010cited by this paper
• The epidermal growth factor variant III peptide vaccine for treatment of malignant gliomas.

  2010cited by this paper
• Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer

  2010cited by this paper
• Prostate cancer as a model for tumour immunotherapy

  2010cited by this paper
• Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.

  2010cited by this paper
• Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium.

  2010cited by this paper
• Human papillomavirus-associated oropharyngeal cancer: a new clinical entity.

  2010cited by this paper
• Cancer Testis Antigen Vaccination Affords Long-Term Protection in a Murine Model of Ovarian Cancer

  2010cited by this paper
• Human papillomavirus-related disease in men: not just a women's issue.

  2010cited by this paper
• Sipuleucel-T

  2010cited by this paper
• Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

  2010cited by this paper
• Increased Intensity Lymphodepletion Enhances Tumor Treatment Efficacy of Adoptively Transferred Tumor-specific T Cells

  2010influential reference
• Analysis of expression profiles of MAGE-A antigens in oral squamous cell carcinoma cell lines

  2009cited by this paper
• Clinical relevance of nine transcriptional molecular markers for the diagnosis of head and neck squamous cell carcinoma in tissue and saliva rinse

  2009influential reference
• Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.

  2009cited by this paper
• Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.

  2009cited by this paper
• Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations

  2009cited by this paper
• EGFRvIII‐Targeted Vaccination Therapy of Malignant Glioma

  2009cited by this paper
• Use of tumour-responsive T cells as cancer treatment.

  2009cited by this paper
• HEAD AND NECK SQUAMOUS CELL CANCER AND THE HUMAN PAPILLOMAVIRUS : SUMMARY OF A NATIONAL CANCER INSTITUTE STATE OF THE SCIENCE MEETING , NOVEMBER

  2009cited by this paper
• Immunotherapy of Head and Neck Cancer: Current and Future Considerations

  2009cited by this paper
• Real-time PCR analysis of genes encoding tumor antigens in esophageal tumors and a cancer vaccine.

  2009influential reference
• HPV & head and neck cancer: a descriptive update

  2009cited by this paper
• E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells.

  2009cited by this paper
• BiTE: Teaching antibodies to engage T-cells for cancer therapy.

  2009cited by this paper
• Immunosenescence and vaccine failure in the elderly

  2009cited by this paper
• Head and neck squamous cell cancer and the human papillomavirus: Summary of a National Cancer Institute State of the Science Meeting, November 9–10, 2008, Washington, D.C.

  2009cited by this paper
• HEAD AND NECK SQUAMOUS CELL CANCER AND THE HUMAN PAPILLOMAVIRUS: SUMMARY OF A NATIONAL CANCER INSTITUTE STATE OF THE SCIENCE MEETING,

  2009cited by this paper
• Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years.

  2009cited by this paper
• Head & Face Medicine BioMed Central

  2009influential reference
• Identification of potential therapeutic targets in human head & neck squamous cell carcinoma

  2009influential reference
• Cancer Statistics, 2008

  2008cited by this paper
• Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers.

  2008cited by this paper
• Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers.

  2008cited by this paper
• Open Access Research

  2008cited by this paper
• Head and neck cancer

  2008cited by this paper
• Examination of oral cancer biomarkers by tissue microarray analysis.

  2008cited by this paper
• Adoptive Cell Therapy for Patients with Melanoma, Using Tumor-Infiltrating Lymphocytes Genetically Engineered to Secrete Interleukin-2

  2008cited by this paper
• EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer.

  2008cited by this paper
• Head and neck cancer: changing epidemiology, diagnosis, and treatment.

  2008influential reference
• Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor.

  2008cited by this paper
• Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial.

  2008cited by this paper
• Targeted therapy in head and neck cancer

  2008influential reference
• Recent advances in head and neck cancer.

  2008influential reference
• EGFR-targeted therapy in colorectal cancer: does immunohistochemistry deserve a role in predicting the response to cetuximab?

  2008cited by this paper
• EGF receptor variant III as a target antigen for tumor immunotherapy

  2008cited by this paper
• Overcoming obstacles to the effective immunotherapy of human cancer

  2008influential reference
• Mechanisms of Tumor Growth and Metastasis in Head and Neck Squamous Cell Carcinoma

  2007cited by this paper
• Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study

  2007cited by this paper
• EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells

  2007cited by this paper
• A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus.

  2007cited by this paper
• Aging and the dendritic cell system: implications for cancer.

  2007cited by this paper
• Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck.

  2007cited by this paper
• Monoclonal antibody mechanisms of action in cancer

  2007cited by this paper
• Advances in Immunotherapy of Multiple Myeloma: From the Discovery of Tumor-Associated Antigens to Clinical Trials

  2007cited by this paper
• Combination Chemotherapy and Radiation of Human Squamous Cell Carcinoma of the Head and Neck Augments CTL-Mediated Lysis

  2006cited by this paper
• Sipuleucel-T

  2006cited by this paper
• Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck.

  2006cited by this paper
• A Phase I Dose Escalation Study with Anti-CD44v6 Bivatuzumab Mertansine in Patients with Incurable Squamous Cell Carcinoma of the Head and Neck or Esophagus

  2006cited by this paper
• Advances in the treatment of locally advanced non-nasopharyngeal squamous cell carcinoma of the head and neck region

  2006cited by this paper
• CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells

  2005cited by this paper
• BiTEs: bispecific antibody constructs with unique anti-tumor activity.

  2005cited by this paper
• Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.

  2005cited by this paper
• Disease-Stage Variance in Functional CD4+ T-Cell Responses Against Novel Pan-Human Leukocyte Antigen-D Region Presented Human Papillomavirus-16 E7 Epitopes

  2004cited by this paper
• Immunotherapy: Bewitched, Bothered, and Bewildered No More

  2004cited by this paper
• Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma.

  2003cited by this paper
• Efficient generation of cytotoxic T lymphocytes against cervical cancer cells by adeno‐associated virus/human papillomavirus type 16 E7 antigen gene transduction into dendritic cells

  2002cited by this paper
• Reinfusion of unprocessed, granulocyte colony-stimulating factor-stimulated whole blood allows dose escalation of 186Relabeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I dose escalation study.

  2002cited by this paper
• Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer.

  2001cited by this paper
• Immunotherapy of metastasis.

  2001cited by this paper
• Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data

  2000cited by this paper
• Detection of T Helper Responses, But Not of Human Papillomavirus-Specific Cytotoxic T Lymphocyte Responses, After Peptide Vaccination of Patients With Cervical Carcinoma

  2000cited by this paper
• Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial.

  1999cited by this paper
• Sequence variation in the monoclonal-antibody-U36-defined CD44v6 epitope

  1997cited by this paper
• Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas.

  1995cited by this paper
• Expression and modulation of CD44 variant isoforms in humans

  1994cited by this paper
• T-cell immunotherapy of cancer.

  1991cited by this paper
• In Vivo Proliferation of Adoptively Transferred Tumor‐Infiltrating Lymphocytes in Mice

  1991cited by this paper
• Selective expansion of a specific anti‐tumor CD8+ cytotoxic T lymphocyte clone in the bulk culture of tumor‐infiltrating lymphocytes from a melanoma patient: Cytotoxic activity and T cell receptor gene rearrangements

  1990cited by this paper
• Current approaches to the adoptive immunotherapy of cancer.

  1988cited by this paper
• Identification and Characterization of a Peptide with Affinity to Head and Neck Cancer

  year unknowncited by this paper

• The Quest for the Next-Generation of Tumor Targets: Discovery and Prioritization in the Genomics Era

  2020cites this paper
• IMMUNO-ONCOLOGY

  2019cites this paper
• Recent advances in the development of novel protein scaffolds based therapeutics.

  2017cites this paper
• The cancer-testis antigen, sperm protein 17, a new biomarker and immunological target in head and neck squamous cell carcinoma

  2017influential citation
• Primary intraosseous squamous cell carcinoma arising in dentigerous cyst: Report of 2 cases and review of the literature

  2015cites this paper
• Emerging drugs for head and neck cancer

  2015cites this paper
• Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients

  2013cites this paper
• Immune alterations and immunotherapy prospects in head and neck cancer

  2013cites this paper
• The immune system and head and neck squamous cell carcinoma: from carcinogenesis to new therapeutic opportunities

  2013cites this paper
• The immune system and head and neck squamous cell carcinoma: from carcinogenesis to new therapeutic opportunities

  2013cites this paper
• Immunotherapy for head and neck cancer patients: shifting the balance.

  2013cites this paper